Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.38 |
| ▸ | KCNA5 | P22460 | 4/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | F11 | P03951 | 1/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.35 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.35 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | LPL | P06858 | 5/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 5/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29983594 | 0.85 | PRMT5 (0.38) | AAK1PRMT5WDR77BACE1BACE2 | |
| SCHEMBL27080846 | 0.81 | CD274 (0.36) | — | |
| SCHEMBL29983196 | 0.78 | PRMT5 (0.35) | AAK1PRMT5WDR77BACE1BACE2 | |
| SCHEMBL29983954 | 0.78 | CD274 (0.38) | — | |
| SCHEMBL27080840 | 0.77 | PDCD1 (0.44) | — | |
| SCHEMBL29984176 | 0.77 | PRMT5 (0.38) | AAK1PRMT5WDR77BACE1BACE2 | |
| SCHEMBL24722595 | 0.76 | DDB1 (0.33) | USP30 | |
| SCHEMBL22675491 | 0.76 | MEN1 (0.37) | KCNA5 | |
| SCHEMBL23027967 | 0.75 | AAK1 (0.41) | AAK1PRMT5WDR77BACE1BACE2 | |
| SCHEMBL4564357 | 0.75 | AAK1 (0.43) | AAK1PRMT5WDR77BACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402917-A1 | COMPOUND AS SMALL MOLECULE INHIBITOR PD-1/PD-L1 AND APPLICATION THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2022-12-22 | — | — | US | disclosed |
| WO-2021063404-A1 | COMPOUND AS SMALL MOLECULE INHIBITOR PD-1/PD-L1 AND APPLICATION THEREOF | 南京明德新药研发有限公司 | 2021-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402917-A1 | COMPOUND AS SMALL MOLECULE INHIBITOR PD-1/PD-L1 AND APPLICATION THEREOF | CD274, PDCD1, PDCD1LG2 | AAK1 1484/4885PRMT5 1499/4885WDR77 3794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.